title: The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy.
abstract: Peripheral blood mononuclear cell subsets, in vitro lymphoproliferative response to leishmanial antigen, and Leishmania-specific serum antibody levels were examined in 11 dogs, naturally infected with L. infantum, and 9 healthy control dogs. A decrease in the percentage of CD4+ T-cells and an increase in the proportion of gammadelta T-cells and sIgG+ B-cells were observed during canine visceral leishmaniasis (CVL). These changes may be responsible for the marked humoral response and the absence of in vitro lymphoproliferation to mitogen and specific parasite antigens. This possibility was supported by the analysis of these subsets after treatment with amphotericin B. One month after therapy, a significant increase in the percentage of CD4+ T-cells and a decrease of gammadelta T-cells and sIgG+ B-cells were observed. At the same time, the lymphocyte blastogenesis assay with leishmanial antigen was positive and the levels of specific antibodies to Leishmania were significantly lower than before the treatment. Five months after therapy, lymphocyte proliferative response to LSA disappeared, antibody and lymphocyte subsets levels returned to those observed during CVL. Therapeutic failure in CVL is associated with the inability of antileishmanial drugs to completely revert the profound immunodepression induced by the infection and prevent relapse.
authors.affiliation: WHO Collaborating Centre for Leishmaniasis, Research Unit for Tropical Diseases and International Health, Centro Nacional de Microbiología, Instituto de Carlos III, Ctra. Majadahonda-Pozuelo, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Moreno
authors.forename: J
authors.initials: J
authors.lastname: Nieto
authors.forename: C
authors.initials: C
authors.lastname: Chamizo
authors.forename: F
authors.initials: F
authors.lastname: González
authors.forename: F
authors.initials: F
authors.lastname: Blanco
authors.forename: D C
authors.initials: DC
authors.lastname: Barker
authors.forename: J
authors.initials: J
authors.lastname: Alvar
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy / Q000276:immunology*; D004285:Dogs; D005260:Female; D007108:Immune Tolerance; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008297:Male; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis
chemical_list: D016692:Receptors, Antigen, T-Cell, gamma-delta; D000666:Amphotericin B